非何杰金氏淋巴瘤市场－全球产业规模、份额、趋势、机会和预测，按疾病类型、药物类别、给药途径、配销通路、地区和竞争格局划分，2020-2030年预测

2024年全球非何杰金氏淋巴瘤市场规模为72.4亿美元，预计到2030年将以7.72%的复合年增长率成长至113.1亿美元。全球非何杰金氏淋巴瘤市场涵盖一系列全面的诊断工具和治疗手段，包括化疗、标靶治疗、免疫疗法（如CAR-T细胞疗法）、放射治疗和干细胞移植，这些疗法均针对不同的淋巴瘤亚型量身定制。市场成长的主要驱动因素是全球非何杰金氏淋巴瘤发病率的上升以及对标靶治疗和免疫疗法等先进治疗方式日益增长的需求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球非何杰金氏淋巴瘤市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型（B细胞淋巴瘤、T细胞淋巴瘤）
  • 依药物类别（单株抗体、抗体药物偶联物、BTK/BCL-2激酶抑制剂、PI3激酶抑制剂、其他）
  • 依给药途径（口服、注射、其他）
  • 按配销通路（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美非何杰金氏淋巴瘤市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲非何杰金氏淋巴瘤市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区非何杰金氏淋巴瘤市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲非霍奇金淋巴瘤市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲非何杰金氏淋巴瘤市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球非何杰金氏淋巴瘤市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• AbbVie Inc
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Seagen, Inc (Pfizer Inc.)
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc
• Merck & Co. Inc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Non-Hodgkin Lymphoma Market, valued at USD 7.24 Billion in 2024, is projected to experience a CAGR of 7.72% to reach USD 11.31 Billion by 2030. The global Non-Hodgkin Lymphoma market comprises a comprehensive array of diagnostic tools and therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies such as CAR T-cell therapy, radiation, and stem cell transplantation, tailored for various lymphoma subtypes. Market growth is primarily driven by the increasing global incidence of Non-Hodgkin Lymphoma and a rising preference for advanced treatment modalities like targeted therapies and immunotherapies.

Key Market Drivers

The Global Non-Hodgkin Lymphoma market is significantly propelled by sustained advancements in targeted therapies and immunotherapies, which offer enhanced treatment efficacy and improved patient outcomes. The continuous development of novel agents specifically designed to target molecular pathways implicated in lymphoma pathogenesis has expanded therapeutic options, particularly for patients with relapsed or refractory disease. For instance, according to Genmab, on June 26, 2024, the FDA approved epcoritamab-bysp, known as EPKINLY(R), for relapsed or refractory follicular lymphoma, representing the first and only T-cell engaging bispecific antibody administered subcutaneously for this indication. This progress not only provides new lifelines for patients but also fuels market expansion through the introduction of premium-priced, innovative treatments.

Key Market Challenges

The substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments, presents a significant impediment to the growth of the global Non-Hodgkin Lymphoma market. These high expenditures directly limit patient access to potentially life-saving interventions, especially in healthcare systems with constrained budgets or in regions lacking robust insurance frameworks.

Key Market Trends

The non-Hodgkin lymphoma market is significantly influenced by the accelerating shift towards personalized medicine, primarily propelled by advanced genomic profiling. This trend emphasizes tailoring treatments based on an individual patient's unique genetic makeup, leading to more targeted and effective therapeutic interventions. For instance, the European Hematology Association's (EHA) guidelines for large B-cell lymphomas and peripheral T-cell lymphomas in 2025 highlight the increasing cruciality of molecular profiling for accurate diagnosis and subtype identification, which directly informs personalized treatment strategies. The expedited delivery of such critical diagnostic information is further advanced, as exemplified by the FDA approval of Thermo Fisher Scientific's Oncomine Dx Express Test in September 2025, designed for companion diagnostics and tumor profiling with results available in as little as 24 hours. This capability enables faster and more precise treatment decisions, enhancing patient outcomes and driving market expansion for advanced diagnostic solutions.

Key Market Players

• AbbVie Inc
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Seagen, Inc (Pfizer Inc.)
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc
• Merck & Co. Inc

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Hodgkin Lymphoma Market, By Disease Type:

• B-cell Lymphomas
• T-cell Lymphoma

Non-Hodgkin Lymphoma Market, By Drug Class:

• Monoclonal Antibodies
• Antibody-Drug Conjugates
• BTK/BCL-2 Kinase Inhibitors
• PI3 Kinase Inhibitors
• Others

Non-Hodgkin Lymphoma Market, By Route of Administration:

• Oral
• Parenteral
• Others

Non-Hodgkin Lymphoma Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Non-Hodgkin Lymphoma Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma Market.

Available Customizations:

Global Non-Hodgkin Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Hodgkin Lymphoma Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (B-cell Lymphomas, T-cell Lymphoma)
  • 5.2.2. By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Non-Hodgkin Lymphoma Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Hodgkin Lymphoma Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Non-Hodgkin Lymphoma Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Non-Hodgkin Lymphoma Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Non-Hodgkin Lymphoma Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Hodgkin Lymphoma Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Non-Hodgkin Lymphoma Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Non-Hodgkin Lymphoma Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Non-Hodgkin Lymphoma Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Non-Hodgkin Lymphoma Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Non-Hodgkin Lymphoma Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Hodgkin Lymphoma Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Non-Hodgkin Lymphoma Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Non-Hodgkin Lymphoma Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Non-Hodgkin Lymphoma Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Non-Hodgkin Lymphoma Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Non-Hodgkin Lymphoma Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Hodgkin Lymphoma Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Non-Hodgkin Lymphoma Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Non-Hodgkin Lymphoma Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Hodgkin Lymphoma Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Non-Hodgkin Lymphoma Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Non-Hodgkin Lymphoma Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Hodgkin Lymphoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol-Myers Squibb Company
• 15.3. AstraZeneca plc
• 15.4. Johnson & Johnson Services, Inc.
• 15.5. Novartis AG
• 15.6. Seagen, Inc (Pfizer Inc.)
• 15.7. Bayer AG
• 15.8. F. Hoffmann-La Roche Ltd
• 15.9. Gilead Sciences Inc
• 15.10. Merck & Co. Inc

16. Strategic Recommendations

17. About Us & Disclaimer